EP1404705A4 - Compositions and methods of using hiv vpr - Google Patents

Compositions and methods of using hiv vpr

Info

Publication number
EP1404705A4
EP1404705A4 EP01922815A EP01922815A EP1404705A4 EP 1404705 A4 EP1404705 A4 EP 1404705A4 EP 01922815 A EP01922815 A EP 01922815A EP 01922815 A EP01922815 A EP 01922815A EP 1404705 A4 EP1404705 A4 EP 1404705A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
hiv vpr
vpr
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01922815A
Other languages
German (de)
French (fr)
Other versions
EP1404705A1 (en
Inventor
Karuppiah Muthumani
David B Weiner
Velpandi Ayyavoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP1404705A1 publication Critical patent/EP1404705A1/en
Publication of EP1404705A4 publication Critical patent/EP1404705A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP01922815A 2000-03-31 2001-03-29 Compositions and methods of using hiv vpr Withdrawn EP1404705A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19349500P 2000-03-31 2000-03-31
US193495P 2000-03-31
US23114100P 2000-09-08 2000-09-08
US231141P 2000-09-08
PCT/US2001/010028 WO2001074163A1 (en) 2000-03-31 2001-03-29 Compositions and methods of using hiv vpr

Publications (2)

Publication Number Publication Date
EP1404705A1 EP1404705A1 (en) 2004-04-07
EP1404705A4 true EP1404705A4 (en) 2004-04-07

Family

ID=26889047

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01922815A Withdrawn EP1404705A4 (en) 2000-03-31 2001-03-29 Compositions and methods of using hiv vpr

Country Status (4)

Country Link
EP (1) EP1404705A4 (en)
AU (1) AU2001249576A1 (en)
CA (1) CA2408904A1 (en)
WO (1) WO2001074163A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254374A1 (en) * 2002-11-21 2004-06-03 Universitätsklinikum Hamburg-Eppendorf Körperschaft des Öffentlichen Rechts Adenoviral vectors for the transfer of specific genes into body cells
BR112012005581B1 (en) 2009-09-16 2021-04-20 Basf Se method to reduce nitrous oxide emission from soils
MX2023008826A (en) 2021-02-01 2023-09-15 Regenxbio Inc Gene therapy for neuronal ceroid lipofuscinoses.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AYYAVOO V ET AL: "Construction of attenuated HIV-1 accessory gene immunization cassettes", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 19, 1 November 1998 (1998-11-01), pages 1872 - 1879, XP004139021, ISSN: 0264-410X *
AYYAVOO V ET AL: "HIV-1 VPR SUPPRESSES IMMUNE ACTIVATION AND APOPTOSIS THROUGH REGULATION OF NUCLEAR FACTOR KAPPAB", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 10, October 1997 (1997-10-01), pages 1117 - 1123, XP002945593, ISSN: 1078-8956 *
MAHALINGAM SUNDARASAMY ET AL: "HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 7, 31 March 1998 (1998-03-31), March 31, 1998, pages 3419 - 3424, XP002268991, ISSN: 0027-8424 *
MUTHUMANI K ET AL: "Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques", JOURNAL OF MEDICAL PRIMATOLOGY, vol. 31, no. 4-5, August 2002 (2002-08-01), pages 179 - 185, XP009025257, ISSN: 0047-2565 *
See also references of WO0174163A1 *
WU X ET AL: "TARGETING FOREIGN PROTEINS TO HUMAN IMMUNODEFICIENCY VIRUS PARTICLES VIA FUSION WITH VPR AND VPX", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 6, 1 June 1995 (1995-06-01), pages 3389 - 3398, XP000608410, ISSN: 0022-538X *

Also Published As

Publication number Publication date
CA2408904A1 (en) 2001-10-11
EP1404705A1 (en) 2004-04-07
AU2001249576A1 (en) 2001-10-15
WO2001074163A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
EP1283707A4 (en) Polymerizable compositions and methods of use
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
PL351552A1 (en) Gypsum compositions and related methods
AU7362301A (en) Bioadhesive compositions and methods of preparation and use
IL155089A0 (en) Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
AU9025701A (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same
AU4570901A (en) Biocidal methods and compositions
AP2001002300A0 (en) Hiv immunogenic compositions and methods
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
HUP0301076A3 (en) Linezolid-crystal form ii and preparation thereof
AU6838501A (en) Enzyme-catalyzed polyamides and compositions and processes of preparing and using the same
AU4215501A (en) Plant acaricidal compositions and methods
AU2002220419A1 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001292667A1 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2002213588A1 (en) Soluble cd1 compositions and uses thereof
PL365602A1 (en) Pharmaceutical compositions and methods for use
AU2001287198A1 (en) Dental restorative compositions and method of use thereof
AU1931602A (en) Cement-containing compositions and method of use
IL153897A0 (en) Pharmaceutical compositions and methods for use
AU2001241771A1 (en) Use of avocado-soybean unsaponifiable preparations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030128

A4 Supplementary search report drawn up and despatched

Effective date: 20040223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

R17P Request for examination filed (corrected)

Effective date: 20030127

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1064884

Country of ref document: HK

17Q First examination report despatched

Effective date: 20050411

17Q First examination report despatched

Effective date: 20050411

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100209

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1064884

Country of ref document: HK